The content on this site is intended for healthcare professionals only
The basis for updates for the 9th edition of UICC TNM classification of malignant diseases
ESMO 2026: Bladder and kidney cancer roundup
ESMO 2026: Prostate cancer roundup
Outpatient administration of xaluritamig for mCRPC: Feasibility and safety
Darolutamide plus ADT and radiotherapy improves metastasis free survival in very high risk prostate cancer
ESMO 2026: Surgery in high-risk localised prostate cancer
Long-term survival benefits of abiraterone in de novo metastatic prostate cancer
Reduced dosing frequency of immune checkpoint inhibitors raises survival concerns in advanced cancer
ESMO 2026: Highlights and analysis
T-cell engagers in mAPMR/mCRPC
ESMO 2026: Advances in NMIBC and MIBC
Perioperative apalutamide plus ADT improves event free survival in high risk localised prostate cancer
